Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $100.0 to $120.0 for Merck & Co over the last 3 months.
An FDA expert panel on Thursday voted against a broader use of Merck (MRK) and Bristol-Myers (BMY) immune checkpoint inhibitors Keytruda and Opdivo. Read more here.